At a P/B of 1.04x and trailing P/E of 22.0x, the market is pricing CNOB as a below-average return franchise rather than rewarding its acquisition-driven scale expansion; the wide gap between TTM P/E (22.0x) and forward P/E (10.5x) implies consensus expects a substantial earnings normalization, likely reflecting post-acquisition cost saves and CECL provision runoff rather than demonstrated structural profitability. Compared with peers trading at 1.2-1.4x book with mid-single-digit or better ROEs (DCOM at 1.22x / 8.7%, NBTB at 1.39x / 11.3%), CNOB's discount appears at least partially justified until NIM recovers meaningfully above 0.8%; if forward earnings materialize, the bank would screen materially cheap on a normalized P/E basis, but execution risk on deposit cost management in the NY market makes this an contingent rather than a secured re-rating.

The DuPont picture for CNOB reveals a bank whose profitability is constrained primarily by asset-side yield rather than cost control: with a 0.8% NIM and ~9x leverage (11% equity/assets), the bank's ROA of 0.2-0.3% leaves little room to close the ROE gap to cost of equity even at improved leverage. The acquisition's front-loaded CECL provisions (spiking to $35.7M in 2025Q2) depressed near-term ROE, but the persistence of muted returns through four consecutive post-deal quarters averaging $38.3M net income suggests the issue is structural spread economics rather than a one-time accounting drag; fee income contribution has also been volatile (-14.1% in 2026Q3 vs. 16.0% in 2025Q3 per reported figures), reducing the reliability of non-interest income as a secondary profitability lever.

The efficiency ratio trajectory is genuinely favorable — declining from 58.9% in 2024Q3 to 53.9% in 2026Q3 (excluding the 87.6% acquisition-quarter spike) — suggesting management's lean operating model and high-touch commercial lending strategy are delivering operating leverage. However, this cost discipline is partially offsetting a NIM that has failed to break above 0.8%, implying deposit costs in the competitive NY/NJ market are rising at least as fast as asset yields can reprice; the 2026Q2 NIM anomaly of -1.8% (purchase accounting distortion) reinforces the view that spread income remains highly sensitive to acquisition accounting effects and warrants close monitoring of core deposit beta in subsequent quarters.

The two-percentage-point decline in equity/assets ratio, while still within a broadly adequate range for a regional commercial lender, reflects the fundamental dilution dynamic of an acquisition that grew assets by 53% while equity grew only 33%. Without explicit CET1, Tier 1, or total capital ratios in the reported data, the 11% equity/assets proxy suggests CNOB has modest headroom above regulatory minimums but limited capacity for aggressive share repurchases or additional M&A without external capital support; the recent dividend step-up to $11.3M quarterly with minimal buyback activity indicates management is prioritizing base dividend sustainability over discretionary capital return, a prudent stance given the thinned buffer.

CNOB occupies an uncomfortable middle ground in the regional peer set: its ROE is closer to OCFC's impaired 2.6% than to NBTB's 11.3% or DCOM's 8.7%, yet its P/B of 1.04x exceeds OCFC's distressed 0.61x, suggesting the market ascribes some value to CNOB's NJ/NY franchise quality despite current return shortfalls. The ROE gap versus NBTB and TRMK appears to be a mix of cyclical (elevated deposit costs in a competitive funding market) and structural factors (purchase accounting distortions and CRE concentration risk), and investors should monitor whether the forward P/E of 10.5x implies convergence toward peer ROEs or simply reflects expected accounting normalization rather than genuine improvement in spread economics.